Lenalidomide and MCL

Based on the findings of a phase II study, the indication for lenalidomide in the U.S. has been expanded to include patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed following the use of two previous therapies including bortezomib.

In the study which included 134 patients with MCL, the overall response rate for lenalidomide was 26% and the median duration of response was 16.6 months. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.